GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications. (PubMed, Eur J Clin Pharmacol) - Oct 25, 2026 - "Growing clinical evidence supports the use of GLP-1-based therapies beyond diabetes management, particularly in patients with cardiovascular disease, chronic kidney disease, or obesity-related heart failure. Further studies will be needed to understand their mechanisms better, long-term safety, and optimal use in clinical practice."
Clinical • Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus
|
|
Caden Jin; Michelle Jang; Rachelle Jang; Woo Kim; Xinyuan Ruan
|